Angiodynamics, Inc. · NASDAQ:ANGO

Angiodynamics — Q1 2021 Earnings Presentation

9 slides from Angiodynamics's earnings presentation, Sep 29, 2020

  1. Slide 1: AngioDynamics First Quarter 2021 Earnings Presentation

    AngioDynamics First Quarter 2021 Earnings PresentationSeptember 29, 2020

  2. Slide 2: Notice Regarding Forward-Looking Statements

    Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strateg

  3. Slide 3: First Quarter FY2021 Highlights

    First Quarter FY2021 Highlights Financial Performance Product Family Year-over-Year Sales Growth (in millions) Q1 FY21 Q1 FY20 YOY Change Revenue $70.2 $66.0 6.3% Gross Margin 50.9% 57.9% (700 bps) Adjusted EPS $0.02 $0.08 ($0.06) Adjusted EBITDA $4.5 $7.3 ($2.8) Cash Used In Operations $5.4 $6.5 Fr

  4. Slide 4: First Quarter FY2021 Results (unaudited)

    First Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q1 FY2021 Q1 FY2020 YOY Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $70,21629,85728,10512,25454,10816,108 $66,04228,91323,15913,97052,93713,105 6.3%3.3%21.4%(1

  5. Slide 5: Guidance and Corporate Developments

    Revenue $278 - $284 million Adjusted EPS $0.00 - $0.05 Corporate Developments Previously disclosed order to National Health Services in the UK for $5.2 million in the first quarter of fiscal year 2021.Gross margin was 50.9% and was primarily impacted by COVID-related operating protocols designed to

  6. Slide 6: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation

  7. Slide 7: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS

    Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Amounts in thousands Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old

  8. Slide 8: Reconciliation of Net Loss to Adjusted EBITDA

    Reconciliation of Net Loss to Adjusted EBITDA Amounts in thousands

  9. Slide 9: Growth through Focus Execution Accountability

    Growth through Focus Execution Accountability

AngioDynamics — Q1 2021 Earnings Presentation on 6ix